Qalsody (tofersen)

Qalsody (tofersen) is a prescription medicine for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) with the SOD1 (superoxide dismutase 1) genetic mutation.

In April 2023, Qalsody was granted accelerated approval by the FDA in the USA.

  • Disease Indications : Amyotrophic Lateral Sclerosis (ALS)
  • Manufacturer : Biogen
  • Usage : Intrathecal Injection
Medicine approved by
  • European Medical Agency (EMA)
  • Food and Drug Administration (FDA)